Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
OftalmologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of comparative effectiveness research
- Publicado em
- 25 abr 2023
- Citações
- 10
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
Scott G Hauswirth, Alan G Kabat, Mandy Hemphill, Karan Somaiya, Laura H Hendrix, Andrea A Gibson
Descritores MeSH
- Dry Eye Syndromes
- Nasal Sprays
- Ophthalmic Solutions
- Phenylalanine
- Varenicline
- Cyclosporine
- Treatment Outcome
- Sulfones
- Humans
Veja também
Estudos relacionados
- Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: A randomized, multicenter, double-masked, vehicle-controlled phase 3 trial
- Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease
- Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
- Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial